Literature DB >> 30078087

Goals of gout treatment: a patient perspective.

Jasvinder A Singh1,2,3.   

Abstract

To assess the goals of gout treatment from a patient perspective, a convenience sample of consecutive patients with doctor-diagnosed gout seen at a community-based outpatient clinic were invited. Sex-stratified nominal groups were conducted until saturation was achieved. Responses were collected verbatim, discussed, and rank-ordered by each participant. Thirty-six patients with doctor-diagnosed gout participated in 12 nominal groups: 6 male only, 5 female only, and 1 group with both. Mean age was 61.9 years (SD, 12.3); mean gout duration was 13.3 years (SD, 12.5); 53% were men, 64% African-American, 42% retired, 47% currently married, 87% were using either allopurinol and/or febuxostat, and 40% had had no gout flares in the last 6 months. The top 5 treatment goals accounted for 91% of all votes and included the following: (1) prevent and better manage flare-ups and improve function (25%), (2) eliminate flare-ups/disease remission (30%), (3) diet and activity modification/lifestyle change (13%), (4) patient education and public awareness (12%), and (5) medication management and minimization of side effects (11%). When examining the top-rated concern for each nominal group, the first two goals were nominated by four groups each, diet/activity modification and medication management by 1 group each, and patient education by 3 groups. There were no differences evident by sex in top-ranked treatment goal. People with gout identified and rank-ordered treatment goals relevant to them. Providers of gout care need to be cognizant of these goals. Disease management concordant with these treatment goals might lead to a more satisfied, informed patient.

Entities:  

Keywords:  Gout; Patient perspective; Therapy goals; Treatment goal

Mesh:

Substances:

Year:  2018        PMID: 30078087     DOI: 10.1007/s10067-018-4243-7

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN: 0770-3198            Impact factor:   2.980


  55 in total

1.  Cost-effectiveness of allopurinol and febuxostat for the management of gout.

Authors:  Eric Jutkowitz; Hyon K Choi; Laura T Pizzi; Karen M Kuntz
Journal:  Ann Intern Med       Date:  2014-11-04       Impact factor: 25.391

Review 2.  Rheumatoid arthritis disease activity measures: American College of Rheumatology recommendations for use in clinical practice.

Authors:  Jaclyn Anderson; Liron Caplan; Jinoos Yazdany; Mark L Robbins; Tuhina Neogi; Kaleb Michaud; Kenneth G Saag; James R O'Dell; Salahuddin Kazi
Journal:  Arthritis Care Res (Hoboken)       Date:  2012-05       Impact factor: 4.794

Review 3.  Chronic gout: epidemiology, disease progression, treatment and disease burden.

Authors:  Richard A Brook; Anna Forsythe; James E Smeeding; N Lawrence Edwards
Journal:  Curr Med Res Opin       Date:  2010-11-04       Impact factor: 2.580

4.  Synovial fluid analysis for diagnosis of intercritical gout.

Authors:  E Pascual; E Batlle-Gualda; A Martínez; J Rosas; P Vela
Journal:  Ann Intern Med       Date:  1999-11-16       Impact factor: 25.391

5.  Target Serum Urate: Do Gout Patients Know Their Goal?

Authors:  Brian W Coburn; Kayli A Bendlin; Harlan Sayles; Kathryn S Hentzen; Michaela M Hrdy; Ted R Mikuls
Journal:  Arthritis Care Res (Hoboken)       Date:  2016-07       Impact factor: 4.794

6.  The experience and impact of living with gout: a study of men with chronic gout using a qualitative grounded theory approach.

Authors:  Karen Lindsay; Peter Gow; Jane Vanderpyl; Phillip Logo; Nicola Dalbeth
Journal:  J Clin Rheumatol       Date:  2011-01       Impact factor: 3.517

7.  Suboptimal physician adherence to quality indicators for the management of gout and asymptomatic hyperuricaemia: results from the UK General Practice Research Database (GPRD).

Authors:  T R Mikuls; J T Farrar; W B Bilker; S Fernandes; K G Saag
Journal:  Rheumatology (Oxford)       Date:  2005-05-03       Impact factor: 7.580

8.  Comparison of drug adherence rates among patients with seven different medical conditions.

Authors:  Becky A Briesacher; Susan E Andrade; Hassan Fouayzi; K Arnold Chan
Journal:  Pharmacotherapy       Date:  2008-04       Impact factor: 4.705

9.  Persistence of monosodium urate crystals and low-grade inflammation in the synovial fluid of patients with untreated gout.

Authors:  E Pascual
Journal:  Arthritis Rheum       Date:  1991-02

10.  Outcome indicators in palliative care--how to assess quality and success. Focus group and nominal group technique in Germany.

Authors:  Tania Pastrana; Lukas Radbruch; Friedemann Nauck; Gerhard Höver; Martin Fegg; Martina Pestinger; Josef Ross; Norbert Krumm; Christoph Ostgathe
Journal:  Support Care Cancer       Date:  2009-08-23       Impact factor: 3.603

View more
  2 in total

1.  Disease modification in gout: a qualitative study of gout expert rheumatologists.

Authors:  Jasvinder A Singh
Journal:  Rheumatol Adv Pract       Date:  2022-01-03

2.  Gout management and outcomes during the COVID-19 pandemic: a cross-sectional internet survey.

Authors:  Jasvinder A Singh; N Lawrence Edwards
Journal:  Ther Adv Musculoskelet Dis       Date:  2020-10-14       Impact factor: 5.346

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.